Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Ajjai Alva,Pam K. Mangat,Elizabeth Garrett-Mayer,Susan Halabi,Damien Hansra,Carmen Julia Calfa,Maged F. Khalil,Eugene R. Ahn,Timothy L. Cannon,Pamela A. Crilley,Julie Gottlieb Fisher,Derrick S. Haslem,Sagun Shrestha,Kaitlyn R. Antonelli,Nicole L. Butler,Sasha L. Warren,Andrew L. Rygiel,Shamika Ranasinghe,Suanna S. Bruinooge,Richard L. Schilsky

Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

2021

PURPOSEThe TAPUR Study is a phase II basket trial that aims to identify signals of antitumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic a...

Keywords:

antitumor activity
Pembrolizumab
in patient
Internal medicine
Text mining
Metastatic breast cancer
Profiling (information science)
Medicine
Oncology
MEDLINE

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations